• Patchliner

    Most versatile automated patch clamp system on the market
  • Patchliner

    In-house production and QC of consumables
  • Patchliner

    More than 10 years experience in assay design and support
  • Patchliner

    All features & benefits of manual patch clamp
  • Patchliner

    More than 100 Patchliners sold worldwide

2019 - MAP4K4 Inhibition Promotes Survival of Human Stem Cell-Derived Cardiomyocytes and Reduces Infarct Size In Vivo

icon pl   Patchliner publication in Cell Stem Cell (2019)

Authors:
Fiedler L.R., Chapman K., Xie M., Maifoshie E., Jenkins M., Golforoush P.A., Bellahcene M., Noseda M., Faust D., Jarvis A., Newton G., Paiva M.A., Harada M., Stuckey D.J., Song W., Habib J., Narasimham P., Aqil R., Schneider M.D.

Journal:
Cell Stem Cell (2019) https://doi.org/10.1016/j.stem.2019.01.013. [In Press, Corrected Proof] 


Highlights: 

  • Human iPSC-cardiomyocytes were used for MAP4K4 target validation and drug discovery
  • MAP4K4 shRNA protects hiPSC-cardiomyocytes from lethal oxidative stress
  • MAP4K4 inhibitors promote hiPSC-cardiomyocyte survival and function
  • MAP4K4 inhibition markedly reduces cardiac ischemia-reperfusion injury in mice

Summary:

Heart disease is a paramount cause of global death and disability. Although cardiomyocyte death plays a causal role and its suppression would be logical, no clinical counter-measures target the responsible intracellular pathways. Therapeutic progress has been hampered by lack of preclinical human validation. Mitogen-activated protein kinase kinase kinase kinase-4 (MAP4K4) is activated in failing human hearts and relevant rodent models. Using human induced-pluripotent-stem-cell-derived cardiomyocytes (hiPSC-CMs) and MAP4K4 gene silencing, we demonstrate that death induced by oxidative stress requires MAP4K4. Consequently, we devised a small-molecule inhibitor, DMX-5804, that rescues cell survival, mitochondrial function, and calcium cycling in hiPSC-CMs. As proof of principle that drug discovery in hiPSC-CMs may predict efficacy in vivo, DMX-5804 reduces ischemia-reperfusion injury in mice by more than 50%. We implicate MAP4K4 as a well-posed target toward suppressing human cardiac cell death and highlight the utility of hiPSC-CMs in drug discovery to enhance cardiomyocyte survival.


Download here

Back to Overview

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
More information Ok